Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998050032) BETA-LACTAM INHIBITORS OF CoA-IT
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/050032 International Application No.: PCT/US1998/009483
Publication Date: 12.11.1998 International Filing Date: 08.05.1998
Chapter 2 Demand Filed: 02.12.1998
IPC:
A61K 31/397 (2006.01) ,A61K 31/4436 (2006.01) ,C07D 205/085 (2006.01) ,C07D 205/095 (2006.01) ,C07D 405/12 (2006.01) ,C07D 409/14 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
397
having four-membered rings, e.g. azetidine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4427
containing further heterocyclic ring systems
4436
containing a heterocyclic ring having sulfur as a ring hetero atom
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
205
Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
02
not condensed with other rings
06
having one double bond between ring members or between a ring member and a non-ring member
08
with one oxygen atom directly attached in position 2, e.g. beta-lactams
085
with a nitrogen atom directly attached in position 3
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
205
Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
02
not condensed with other rings
06
having one double bond between ring members or between a ring member and a non-ring member
08
with one oxygen atom directly attached in position 2, e.g. beta-lactams
09
with a sulfur atom directly attached in position 4
095
and with a nitrogen atom directly attached in position 3
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
14
containing three or more hetero rings
Applicants:
SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza Philadelphia, PA 19103, US (AllExceptUS)
BONDINELL, William, E. [US/US]; US (UsOnly)
WINKLER, James, David [US/US]; US (UsOnly)
Inventors:
BONDINELL, William, E.; US
WINKLER, James, David; US
Agent:
DINNER, Dara, L. ; SmithKline Beecham Corporation Corporate Intellectual Property, UW2220 709 Swedeland Road P.O. Box 1539 King of Prussia, PA 19406-0939, US
Priority Data:
60/046,08009.05.1997US
Title (EN) BETA-LACTAM INHIBITORS OF CoA-IT
(FR) INHIBITEURS BETA-LACTAMINE DE CoA-IT (TRANSACYLASE INDEPENDANTE DE COENZYME A)
Abstract:
(EN) This invention relates to a novel method for treating disease or disorders mediated by the lipid inflammatory mediators, arachidonic acid, its metabolites and/or platelet activating factor (PAF), which method comprising administering to a mammal in need thereof an effective Coenzyme A independent transacylase (CoA-IT) inhibiting amount of a compound of formula (I). This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of formula (I).
(FR) L'invention a trait à un nouveau procédé permettant de traiter des maladies ou des troubles dans lesquels interviennent des médiateurs d'inflammation lipidiques, l'acide arachidonique, ses métabolites et/ou le facteur d'activation des plaquettes (PAF). Le procédé comporte l'administration à un mammifère nécessitant un tel traitement d'une quantité efficace, en termes d'action inhibitrice, d'un composé de transacylase indépendante de coenzyme A (CoA-IT) représenté par la formule (I). L'invention a également trait à un procédé permettant de traiter ou de réduire l'inflammation chez un mammifère nécessitant un tel traitement, ce procédé comportant l'administration audit mammifère d'une quantité efficace d'un composé ou d'une composition représenté(e) par la formule (I).
Designated States: CA, JP, US
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP1011663JP2001524132 CA2288986